Other manifestations of HIV vasculopathy

N. G. NAIDOO, M.B. CH.B., F.C.S. (S.A.)
Department of Surgery, Groote Schuur Hospital, University of Cape Town
S. J. BENINGFIELD, M.B. CH.B., F.F.RAD. (D.) (S.A.)
Department of Radiology, Groote Schuur Hospital, University of Cape Town

Summary

Descriptions of the numerous manifestations of human immunodeficiency virus (HIV) infection affecting almost every organ system have abounded in recent publications. Multiple radiological, clinical and postmortem reports have recorded the cerebral, pulmonary, cardiac, renal, rheumatological and gastrointestinal pathologies in HIV-infected individuals, ranging from the bizarre to the mundane. Large-vessel HIV-related vascular manifestations have previously been reported in the surgical literature. We describe and review the manifestations of HIV-associated vasculopathy as it pertains to the cerebral, cardiovascular, mesenteric and renal circulations.

Since the first descriptions of acquired immune deficiency syndrome (AIDS) in homosexual men in San Francisco in 1981, HIV has commonly been associated with and implicated in the pathogenesis of vascular disease. The South African experience of HIV-related aneurysms occurring in young HIV-infected individuals suggested a distinct clinicopathological entity, based on distribution, morphological description and histopathological findings.1,2 Less convincing, but occurring more frequently in younger HIV-infected South Africans, has been an apparently unique type of vascular occlusive disease.3 This has generally been encountered in those individuals with advanced disease and significant immunocompromise. These manifestations are not unique to South Africa, and have also been described elsewhere.4

Although many reports preceded the highly active antiretroviral treatment (HAART) era, they still occur in areas where HAART is not available. Very few descriptions of HIV-associated vasculopathy in other sites, such as the cerebral, coronary, renal or mesenteric territories, have been reported in the surgical literature. This is understandable, considering that much of the pathology manifests as systemic vasculitides, with very limited surgical treatment options. Systemic vasculitides, however, have been reported in less than 1% of HIV patients, predominantly affecting skin, muscle and nerves and very rarely other organ systems.

The advent of HAART has dramatically modified outcomes in HIV/AIDS, with concerns now being expressed about the older HIV population group exposed to long-term HAART now being more susceptible to precocious and/or accelerated atherosclerotic vascular disease.

Cerebrovascular disease

HIV and stroke

Neurological disorders are not uncommon in patients with HIV-1 infection. Post mortem studies have shown that involvement of the CNS is estimated to occur in between 70% and 90% of HIV-infected patients. Approximately 10 - 20% of HIV-infected patients present with neurological symptoms as a first manifestation.5,6 Multiple pathologies contribute to the aetiology of stroke in HIV-1-infected patients. The vast majority are associated with CNS infections and/or tumours. Only a small proportion are related to vascular pathology directly attributable to or associated with the HIV infection itself.7

Overall, clinical neurological manifestations occur in up to 40% of patients with AIDS, but stroke is thought to occur in as few as 1.3% of cases, although the true incidence of stroke in HIV patients is not accurately known. HIV-positive patients with strokes generally have a poor survival (mean of ~4 months).

Cerebral infarction rates range from 6% to 34% in autopsy series, but few have clinical correlation. In one review of 6 clinical series, the stroke prevalence ranged from 0.5% to 34%.8 A cohort study of 772 HIV-positive patients reported a 0.8% prevalence for transient ischaemic attacks (TIA) and 1.2% for stroke, with an estimated annual incidence rate of
216 per 100 000. The prevalence was highest in the more advanced form of the disease. In another clinical review of 1 600 HIV patients, Pinto found an incidence of 0.75%, which was higher than the risk of stroke in a comparable HIV-negative group (0.025%). In an autopsy review of 763 patients only 1.3% of HIV-infected patients had a stroke syndrome. Pathologically detected ischaemic infarcts were more common (68%).

Connors et al., in an autopsy study excluding other aetiologies associated with stroke in HIV-positive cases, found only 1 TIA recorded clinically in 10 cases (of a total of 183 autopsies) with cerebral infarcts directly attributable to HIV vasculopathy.

Numerous autopsy, radiological and clinical studies suggest an association between stroke and HIV infection related to vascular pathologies, coagulopathies or cardio-embolism. HIV-related vasculopathy has generally been described in association with co-infections in HIV-infected patients.

In a recent study, Mochan et al. analysed 35 HIV, HAART-naïve patients with stroke using CT imaging. They found cerebral infarction in 33 (94%) and intracerebral haemorrhage in 2 (6%). In 31 patients the infarcts occurred in the distribution of the anterior circulation. Conventional cerebral angiography, performed in 22 patients, was normal in 15. The seven patients revealed: arterial thrombosis in 3 patients (internal carotid artery in 2, middle cerebral artery in 1, diffuse intracranial vasculopathy with multiple stenotic lesions involving small and medium-size vessels in 2 cases, low-grade carotid bifurcation stenosis in 1 case, and extracranial internal carotid artery dissection in 1 case. In their analysis, 10 patients had more than 1 underlying cause for the stroke, including meningitis (25%), potential cardioembolic cause (9%), coagulopathy (49%) and hypertension (2 patients). Only 4 patients had a stroke directly attributable to HIV-related vasculopathy or vasculitis (with varicella zoster co-infection in 1 case).

HIV-related cerebral vasculitis has generally been associated with CNS infections, lymphoproliferative disorders or drugs. There are 2 South African retrospective, case-controlled studies comparing stroke rates in young patients (age under 46 years). Hoffman et al. compared 32 HIV-positive, HAART-naïve stroke patients with 22 HIV-negative controls with stroke. The distributions of infarcts were similar in both groups on CT or MR imaging and micro-infarcts were not documented in either group. Conventional angiography (not done in all cases) demonstrated more internal carotid artery and middle cerebral artery occlusions in the HIV group than in the control group. Classic risk factors for stroke were infrequent in the HIV group. Patel et al. reviewed 293 black patients aged between 15 and 44 years with stroke (245 cerebral infarctions and 48 haemorrhages). There were 56 HIV-positive, HAART-naïve patients (51 with cerebral infarction and 5 with cerebral haemorrhage). No specific aetiology was found in 68.9% of the cases. There was no difference in cardioembolic aetiology between the groups. Conventional angiograms were performed in 158 patients, of which 62% were positive. There was no statistical difference in the number of internal carotid artery (ICA) or middle cerebral artery (MCA) occlusions between the groups, although there was a trend towards more ICA and MCA occlusions in the HIV group.

Tipping et al. reviewed 67 HIV-positive patients (of which 61 patients were under 45 years of age). Cerebral infarction occurred in 96% (64 patients) and intracerebral haemorrhage in 4%. HIV-positive patients did not have classic risk factors for stroke. A distinct aetiology for stroke was identified in 81% of patients: infections (28%), coagulopathy (19%), cardioembolism (14%), unknown (19%) and HIV-associated vasculopathy (20%). Occlusion of the common carotid artery (CCA) or ICA was demonstrated in 7 (11%) patients. Autopsy findings in 1 patient revealed thrombotic occlusion of the right carotid artery. Sections of the carotid bifurcation revealed adventitial fibrosis and neovascularisation, intimal fibrosis, fragmentation of the internal elastic lamina, medial degeneration and lymphoplasmacytic infiltrate. Six patients (9%) had intracranial vascular pathology not associated with any other aetiology for stroke. Angiography revealed medium vessel occlusion, with or without ectasia, and areas of vascular stenoses involving the circle of Willis and cerebral arteries including their proximal divisions.

In the Edinburgh HIV autopsy cohort, 10 cerebral infarcts (of a total of 183 cases with cerebral infarcts) were ascribed to HIV vasculopathy. Histopathology of the intracranial vessels revealed intimal thickening, dilatation of the perivascular spaces with areas of pigment deposition, microvessel mineralisation and perivascular inflammatory cells. Interestingly, no vasculitis (arterial wall inflammatory infiltrate) was found. The authors suggest an exhaustive search for stroke aetiology before ascribing it to HIV vasculopathy.

Many of the studies evaluated stroke in HIV-positive patients not receiving HAART. In a recent study, Ortiz et al. evaluated 82 HIV-positive patients. Forty-eight patients (58%) were on HAART. Seventy-five patients (92%) had a diagnosis of HIV prior to the stroke. Among the 77 patients who had ischaemic strokes, 10 had atherosclerosis involving large arteries (4 CCA/ICA, 5 MCA and 1 vertebral-basilar stenoses). Fifteen patients (19%) had small-vessel occlusion confirmed on imaging studies. Other aetiologies included vasculitis in 10 (23%), vertebral artery dissection in 1, coagulopathy in 7 and a potential cardioembolic source in 15. Classic risk factors were present: tobacco smoking (51%), hypertension (42%) and diabetes mellitus (7%). Interestingly, hyperlipidaemia was uncommon. Patients with atherothrombotic strokes were older (45.3 versus 40.1 mean age) than those with non-atherothrombotic strokes. Sixty-eight per cent of patients with atherothrombotic strokes had received HAART. However, the use of HAART did not correlate with the type of ischaemic stroke.

Stroke due to co-viral vasculitis in HIV-positive patients has been described. These patients usually present with advanced HIV infection. Varicella zoster vasculitis (VZV) associated with stroke has been described following zoster ophthalmicus and zoster oticus. Zoster vasculitis is a granulomatous vasculitis with multinucleate giant cells, viral antigens, viral DNA and Cowdry A inclusions seen in arterial walls. Diagnosis is usually accomplished by lumbar puncture with cerebrospinal fluid (CSF) analysis and serology. Ortiz et al. described a case associated with the Ramsay Hunt syndrome in which MRI demonstrated a pontine infarct. There were multiple stenotic areas involving distal vertebral and basilar arteries, as well as the arteries related to the circle of Willis on MRI and conventional angiography. Treatment consists of gancyclovir, prednisone and HAART.

Primary angitis of the CNS (PACNS), first described in 1959, is an uncommon vasculitis predominantly involving
HIV and cerebral aneurysms

HIV-related intracranial aneurysms have been described in paediatric and, more recently, adult populations. Dubovsky et al. reported on 5 paediatric cases and reviewed an additional eight paediatric cases from the literature. The patient was anticoagulated with documented neurological improvement.

Stroke secondary to CCA/ICA atherosclerotic plaques has been well studied in HIV-negative patients. Carotid endarterectomy and carotid angioplasty with stenting, both currently in treating significant carotid stenoses, have played a major role in reducing stroke. Studies have indicated an increasing incidence of cardiovasculary and cerebrovascular disease in the HAART era. Currenty there does not appear to be an increasing incidence of stroke associated with carotid bifurcation plaques in HIV-infected patients in the HAART era. Regina et al. reported 2 patients with asymptomatic high-grade ICA stenosis of approximately 80%, with carotid duplex showing progressive stenosis in both patients. Both CCA and external carotid arteries (ECA) were normal. Both were young patients (<40 years). Both were on long-standing HAART including a protease inhibitor (PI). At surgery, both the lesions were found to be focal, thick, fibrotic ICA plaques without endarterectomy plane. A resection of the proximal ICA with reimplantation to the ECA was performed in both. Histology revealed an intimal lesion with fibro-fatty plaque, fragmentation of the internal elastic lamina, medial scarring and occasional perivascular lymphocytes around the vasa vasoorum. A lymphoplasmacytic infiltrate was found in the intima and media. HIV-1 was isolated from biopsy specimens.

HIV-related cerebral aneurysms

HIV-related intracranial aneurysms have been described in paediatric and, more recently, adult populations. Dubovsky et al. reported 5 paediatric cases and reviewed an additional eight paediatric cases from the literature. Seven patients acquired the HIV infection perinatally. Diagnosis was based on neuroimaging, CSF analysis, and exclusion of current infection and other CNS pathology on screening. Nogueras et al. reported a case of recurrent strokes with primary angiitis of the CNS in an HIV-infected patient. MRA findings of segmental stenoses involving the distal ICA and basilar arteries were documented, with marked luminal narrowing. Histopathological findings documented lymphocytic vasculitis of the basal meningeal and parenchymal vessels. A fibrous vasculitis was found in vessels of the circle of Willis with intimal fibrosis, medial destruction and lymphoplasmacytic infiltrate with multinucleated giant cells. PACNS generally had a poor prognosis, most cases being reported in autopsy series. Whether HAART will alter the incidence or prognosis with PACNS remains speculative.

Stroke secondary to spontaneous artery dissection in HIV-infected patients has been reported. Felicio et al. reported a case in an HIV-infected patient with Wallenberg’s syndrome (ipsilateral cerebellar infarct) secondary to a vertebral artery dissection. The patient was anticoagulated with documented neurological improvement.

Stroke secondary to CCA/ICA atherosclerotic plaques has been well studied in HIV-negative patients. Carotid endarterectomy and carotid angioplasty with stenting, both currently in treating significant carotid stenoses, have played a major role in reducing stroke. Studies have indicated an increasing incidence of cardiovasculary and cerebrovascular disease in the HAART era. Currently there does not appear to be an increasing incidence of stroke associated with carotid bifurcation plaques in HIV-infected patients in the HAART era. Regina et al. reported 2 patients with asymptomatic high-grade ICA stenosis of approximately 80%, with carotid duplex showing progressive stenosis in both patients. Both CCA and external carotid arteries (ECA) were normal. Both were young patients (<40 years). Both were on long-standing HAART including a protease inhibitor (PI). At surgery, both the lesions were found to be focal, thick, fibrotic ICA plaques without endarterectomy plane. A resection of the proximal ICA with reimplantation to the ECA was performed in both. Histology revealed an intimal lesion with fibro-fatty plaque, fragmentation of the internal elastic lamina, medial scarring and occasional perivascular lymphocytes around the vasa vasoorum. A lymphoplasmacytic infiltrate was found in the intima and media. HIV-1 was isolated from biopsy specimens.

HIV-related cerebral aneurysms complicated by symptomatic ischaemic infarcts have been described as part of the immune-reconstitution inflammatory syndrome (IRIS). An immune-mediated vasculitis is thought to be the basis of IRIS in response to improved immunocompetence with HAART, generally after less than 1 year of therapy. MRA in this case revealed multiple fusiform aneurysms involving the circle of Willis. No other aetiology was found on screening. The patient improved on HAART, acyclovir and aspirin.

Cerebral vasculopathy with aneurysm formation has also been described in young HIV-positive adults. Kossovorot et al. described 2 HIV-positive patients with strokes and MCA territory infarcts. MRA revealed multiple fusiform aneurysms, ectasia and stenotic areas involving small and medium-sized arteries. One patient had an ipsilateral thomboembolic distal ICA aneurysm. VZV was probably causally related in 1 patient.

Tipping et al. described stroke in a 27-year-old female patient with neuroimaging findings of fusiform aneurysmal dilatation of the arteries of the circle of Willis. Autopsy findings revealed fusiform dilatation of left ICA, and left MCA branches. Thrombus was present in the MCA and anterior divisions. Histology demonstrated a fusiform aneurysm with intimal fibrosis with hyalinisation, medial atrophy and fragmentation of the elastic lamina. Alcian blue staining showed depositions of mucopolysaccharides in the intima and media. Subarachnoid haemorrhage (SAH) has been described in association with HIV-related cerebral aneurysms in adults. Hamilton et al. reported a 34-year-old HIV-positive male on HAART (CD4 count 66 cells/µl) with end-stage renal failure, cardiomyopathy and left-sided weakness. CTA demonstrated an SAH with multiple fusiform and giant saccular aneurysms. He was treated expectantly. Taylor et al. reported 3 patients with SAH and cerebral aneurysms in young HIV-infected adults with low CD4 counts. They postulated intracranial arterial dissection as the pathogenic process associated with SAH in 2 of their patients. Two of the patients were treated with endovascular techniques: segmental vessel trapping using GDC coils in 1 patient and partial coil embolisation of a false aneurysm in the other (Figs 1 and 2).

Modi et al. recently reported 3 cases of HIV-related intracranial aneurysms presenting with cognitive impairment, SAH and seizures respectively. All had multiple fusiform...
intracranial aneurysms (1 patient thought to have a saccular aneurysm was found to have a fusiform aneurysm at surgery and was not treated). A screen for other aetiology was negative in all 3 cases. On review of the literature, they discovered an additional 11 patients presenting with strokes, headache and SAH, 7 of whom had saccular (probably congenital) aneurysms, with the remainder being fusiform aneurysms.

HIV-related aneurysms occur in young adults (under 45 years) with advanced HIV infection (CD4 count less than 200 cells/µl). Patients are generally HAART- naïve. There is some evidence that HAART to an extent improves the clinical course of HIV-related aneurysms in paediatric patients. Whether HAART will influence outcomes in HIV-related aneurysms in adults is still to be defined. Novel endovascular strategies are now available to treat selected individuals.

HIV and cerebral venous thrombosis

This is a rare manifestation in HIV-infected patients. Meyohas et al. reported a case of superior sagittal sinus (SSS) thrombosis in a patient with dual primary infection with HIV and CMV, both viruses known to be associated with vasculitis.32 The thrombophila screen was normal. Prendki et al. reported SSS and transverse sinus (TS) thrombosis in 2 HIV-infected patients as part of a rapid immune reconstitution inflammatory syndrome (IRIS).33 Both patients were initially treated for cryptococcal meningitis. One patient subsequently had his HAART regimen revised, while HAART was commenced in the second patient. Both patients developed progressive neurological symptoms following a delay of 1 - 2 months of HAART. MR imaging revealed SSS and TS thrombosis in both patients. Anticoagulation was instituted with variable clinical response.

Cardiovascular disease

Common cardiovascular manifestations in HIV-infected individuals include pericardial effusions, myocarditis, dilated cardiomyopathy, systemic hypertension (up to 74% of HIV-infected patients in the HAART era), HIV-associated pulmonary hypertension and AIDS-related cardiac tumours.34,35

HIV and coronary vasculitis

A wide variety of vasculitides unrelated to HIV may affect the coronary arteries, including polyarteritis nodosa, Henoch-Schönlein purpura and drug-induced vasculitis.35,36 Shingadia et al. reported a case of Takayasu’s disease in an HIV-infected adolescent.37 Kawasaki-like syndromes have also been reported.3,38 Kawasaki disease is an acute vasculitic syndrome of unknown aetiology occurring in paediatric patients under 5 years of age. The diagnosis is based on clinical features includ-
HIV and atherosclerotic coronary artery disease

Cardiology publications have noted the increasing frequency of coronary artery disease (CAD) in HIV-infected patients on HAART. There is still considerable debate regarding the exact aetiology of HIV-related CAD which may be due to HIV, HAART or HAART-associated metabolic syndrome, or a combination thereof. There is agreement that overall HAART has considerably modified outcomes in HIV/AIDS, reducing opportunistic infection, improving life expectancy and quality of life. However, concerns have now been raised regarding premature or accelerated atherosclerotic cardiovascular, cerebrovascular and peripheral arterial disease in the older HIV cohort on longstanding HAART.

The pathogenesis of atherosclerotic CAD is likely to be multifactorial. The association between low CD4 counts and CAD has been inconsistent. The dysmetabolic profile of HAART regimens, especially protease inhibitor (PI) based therapies, with increased total cholesterol, increased low-density lipoprotein (LDL), hyperglycemia, insulin resistance and lipoprotein abnormalities, has been implicated. HIV-infected patients with classic risk factors for CAD (age, personal or family history, diabetes mellitus, smoking, hyperlipidaemia) on HAART may be at increased risk of CAD.

Bocca et al., in a review of 129 HIV-infected patients with CAD (mean age of 42 years) found no correlation between CD4 count and CAD. Acute myocardial infarction (MI) was the initial clinical presentation in 77% of patients. Forty-seven percent of patients had multiple vessel disease (18% had 2 vessel and 35% had 1 vessel disease). In one study mortality associated with a first MI approached 24%. Of concern is the finding that as many as 69% of patients were less than 50 years old.

Coronary pathology in these patients has been reported as distinct (diffuse and circumferential intimal thickening, atherosclerotic plaques and unusual proliferation of smooth muscle with luminal protrusions). Some of these features are seen in transplant vasculopathy.

Rickerts et al., in a retrospective analysis of the Frankfurt HIV Cohort Study, found a fourfold increase in the annual incidence of CAD after the commencement of HAART. Klein et al. reported a coronary event rate of 5.5/1,000 patient years in the HAART era, higher than that of a control group. While the relative risk of increase in CAD in HIV-infected patients on HAART approaches 25% per annum, the absolute increase in these patients is small.

HIV and HAART have confounded classic cardiac risk evaluation and categorisation. Other models beyond the Framingham score are currently being evaluated. Surrogate markers for the detection of subclinical atherosclerotic CAD are being evaluated (including coronary artery calcium score, high sensitivity C-reactive protein (CRP) and carotid intima media thickness).

Medical therapy for atherosclerotic CAD in these patients is along currently established guidelines. Caution should be exercised in the prescription of pharmaceutical agents, especially lipid-lowering agents metabolised by the same pathway as PIs. Pravastatin, and to a lesser extent atorvastatin, is preferred to simvastatin and lovastatin.

In contradistinction to the large cardiology experience with percutaneous coronary intervention (PCI) in non-HIV patients, the experience with PCI in HIV-infected patients is limited. Treatment with percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting (CS) has been described, with promising early outcomes.

Intermediate outcomes with PCI have also been reported. Bocca et al. reviewed their experience with 20 HIV-infected patients with acute coronary syndrome. Initially 4 patients received thrombolysis, 2 patients underwent PTCA and 7 had CS. The remainder of the patients were treated medically. At a mean follow-up of 38 months (range 2 - 72 months) 18 cardiovascular events, including 1 death, occurred in 50% of patients. None of the patients with a previous PCI needed target vessel revascularisation (TVR). Two patients had CS and 3 patients had a coronary artery bypass graft (CABG). In a similar case-controlled study, Hsue et al. showed similar results.

Matetzky et al. compared HIV-infected patients with acute MI with a non-HIV control group. At 15 months follow-up the HIV-infected group had a higher incidence of recurrent MI and TVR, independent of type of HAART regimen. Similar findings at 36-month mean follow-up were noted by Escaut et al.

Boccare et al. evaluated the outcomes of PCI in 50 HIV-infected patients and compared them with 50 non-HIV patients. The procedural success was 98% in each group. Mean follow-up was 625 days. Clinical restenosis, TVR, major adverse cardiac events (MACE)-free and MI rates were not significantly different between the groups.

CABG in HIV-patients has been reported in HIV-infected patients with or without HAART. Blyth et al. reviewed their experience with cardiopulmonary bypass in 49 HIV-infected, HAART-naive patients for a range of indications (CABG in 3). The perioperative mortality was 6%, with 34.7% mor-
bidity. Evolving criteria for cardiac surgery in HIV-infected patients at this unit included a CD4 count of over 400 cells/µl and the absence of AIDS. Tractitis et al. performed 27 cases of CABG with no perioperative deaths in this subgroup. Freedom from a composite endpoint of angina, death, MI, repeat revascularisation and congestive cardiac failure at 3 years was 81%. Similar results were reported by Castillo et al. With a follow-up of 8.2 years, the long-term mortality was 10.8%. Results of a multicentre case-control study, comparing CABG in HIV-infected patients, with CABG in HIV-negative patients have been published recently. Thirty-day outcomes (death, MI, stroke, mediastinitis, and reintervention) were similar in both groups. At follow-up (median: 42 months) MACE was significantly higher in the HIV-infected group (42% v. 25%), predominantly due to the need for PCI of progressive occlusive disease in the native coronary arteries (not graft related).

Visceral HIV-related vasculopathy
Vascular involvement of the mesenteric circulation in HIV-infected individuals is not commonly described.

HIV and mesenteric vasculitis
Polyarteritis nodosa-like syndromes and nonspecific systemic necrotising vasculitis are the commonest vasculitides described in HIV-infected individuals, typically involving skin, muscle and peripheral nerves. Reports of mesenteric or renal involvement are rare compared with classic polyarteritis nodosa (PAN). Coinfection with current hepatitis B in these cases is rarely described. Acute flare-ups are not seen in the HIV population.

Sambatakou et al. reported a case of acute mesenteric ischaemia in a 31-year-old HIV-infected, HAART-naïve patient (with CD4 count of 142 cells/µl and viral load of 217,400 copies/ml). Colonoscopy revealed rectal and sigmoid mucosal erosions. The patient underwent a laparotomy with resection of 125 cm of ileum. The diagnosis of mesenteric artery thrombosis was entertained at laparotomy. Histopathology revealed a necrotising vasculitis involving small and medium-sized vessels of the gut, with gut ulceration and ischaemia. A renal biopsy for progressive renal dysfunction revealed IgA deposits in the capillaries (a feature of PAN). He was treated with cyclophosphamide, prednisone and HAART and recovered well.

Cytomegalovirus (CMV) vasculitis occurs in immunocompromised individuals, causing colitis. However, descriptions of CMV colitis in HIV-infected individuals have not paralleled the HIV pandemic.

Acute mesenteric ischaemia has been documented as a complication of treatment. Zaraa et al. described acute mesenteric ischaemia in an HIV-infected 44-year-old woman with Kaposi’s sarcoma following treatment with interferon-A2b and the development of the haemolytic uraemic syndrome. Rapid clinical improvement followed withdrawal of interferon.

HIV and chronic mesenteric ischaemia
Mesenteric large-vessel involvement is unusual in HIV-infected individuals. A large case series profiling 92 HIV-related aneurysms in 28 patients identified only 3 visceral aneurysms. All 3 were asymptomatic and always associated with aortic aneurysms. One coeliac artery aneurysm was thrombosed. There were 2 saccular aneurysms and 1 fusiform aneurysm.1,2

Chahid et al. reported a case series of 14 patients with chronic mesenteric ischaemia treated by percutaneous transluminal angioplasty (PTA) with or without a stent.17 A 32-year-old female patient with antiphospholipid syndrome was HIV positive, with early-onset mesenteric atherosclerosis. She presented with weight loss and post-prandial pain. She underwent a PTA and stent with a good technical and clinical outcome on follow-up.

Intraparenchymal splenic artery calcification in a branching configuration has been reported in HIV-infected paediatric patients. The significance of this finding remains obscure.

HIV and abdominal venous thrombosis
Portal and splenic vein thrombosis has been rarely reported in HIV-infected individuals. Crum-Cianflone et al. evaluated 165 HIV-infected patients for venous thrombosis and found 17 patients (3.7%) with 19 thrombotic events. Two were located in the splenic and portal veins. All patients were on HAART. All had identifiable risk factors for venous thrombosis. In their review of the literature, they identified 9 cases of portal vein thrombosis reported in HIV-infected individuals. The pathogenesis of venous thrombosis in HIV-infected patients is probably multifactorial. Indinavir, a PI, has been associated with portal vein thrombosis.25

Renal HIV-related vasculopathy
Renal manifestations of HIV include HIV-associated nephropathy (HIVAN), ‘collapsing glomerulopathy’, IgA glomerulonephritis, microangiopathic nephropathy (haemolytic uraemic syndrome), immune complex (systemic lupus-like) syndrome and mixed cryoglobulinaemic vasculitis.

There is a growing awareness of PAN-like syndromes in HIV-infected patients. PAN-like syndromes in HIV-infected individuals, although less common compared with classic PAN, can also involve the renal circulation. Sagcan et al. reported a 29-year-old HIV-positive patient who presented with spontaneous bilateral perirenal haematomas. An renal angiogram showed multiple intraparenchymal microaneurysms typical of PAN. A unilateral nephrectomy was performed and the diagnosis of PAN was confirmed on histology.

Adjunctive treatment invariably includes azathioprine or cyclophosphamide, prednisone and HAART. Prognosis with bilateral spontaneous perirenal haematomas associated with PAN is reported to be poor, with 5 of 9 patients dying within 6 months. Less invasive treatment strategies have evolved to treat ruptured intrarenal aneurysms, including transcatheter embolisation.

HIV-related large-vessel renal artery aneurysm or occlusion is rare. Nair et al., in reviewing a large institutional series of HIV-related aneurysms, reported 1 patient with severe hypertension. The 18-year-old patient was found to have a large suprarenal abdominal aortic aneurysm (AAA) with renal involvement and a non-functioning right kidney. She was treated by elective repair of the suprarenal AAA with multiple side-arm grafting to the visceral and left renal arteries. A right nephrectomy was performed. Unfortunately the patient died following acute renal failure secondary to occlusion of the graft to the left renal artery.
Conclusion

Vasculitides, although uncommon in HIV-infected individuals, should trigger an exhaustive screen for other etiologies (including co-infections, lymphoproliferative disease, and autoimmune disorders) before ascribing it to HIV. Whether HAART will alter the incidence of these vasculitides, and the outcomes associated with some of the manifestations, including intracranial aneurysms, remains speculative. Whether an increased roll-out of HAART in less-developed countries will translate into a delayed increased risk of atherothrombotic vascular disease, as expressed in developed countries, remains to be defined. HAART has affected conventional medical management guidelines for established atherothrombotic vascular disease, especially lipid management, in HIV-infected patients, and these adjustments should be incorporated in our current management of these patients.

REFERENCES


